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Infectionwithmanyemergingviruses,suchasthehemorrhagicfeverdiseasecausedbytheﬁloviruses, Marburg (MARV), and Ebola
virus(EBOV),leavesthehostwithashorttimeframeinwhichtomouseaprotectiveimmuneresponse.Inlethalcases,uncontrolled
viral replication and virus-induced immune dysregulation are too severe to overcome, and mortality is generally associated with
a lack of notable immune responses. Vaccination studies in animals have demonstrated an association of IgG and neutralizing
antibody responses against the protective glycoprotein antigen with survival from lethal challenge. More recently, studies in animal
models of ﬁlovirus hemorrhagic fever have established that induction of a strong ﬁlovirus-speciﬁc cytotoxic T lymphocyte (CTL)
response can facilitate complete viral clearance. In this review, we describe assays used to discover CTL responses after vaccination
or live ﬁlovirus infection in both animal models and human clinical trials. Unfortunately, little data regarding CTL responses have
been collected from infected human survivors, primarily due to the low frequency of disease and the inability to perform these
studies in the ﬁeld. Advancements in assays and technologies may allow these studies to occur during future outbreaks.
1.Introduction
The Filoviridae family contains the two genera, Ebolavirus
and Marburgvirus.T h eMarburgvirus genus contains a
single species: Lake Victoria Marburg virus (LVMARV). The
Ebolavirus genus consists of the four species of Ebola virus
(EBOV): Zaire EBOV (ZEBOV), Sudan EBOV (SEBOV),
Reston EBOV (REBOV), and Ivory Coast EBOV (ICEBOV).
After a recent outbreak in Uganda, a ﬁfth species of EBOV
has been proposed [1].
Filoviruses are enveloped, nonsegmented, negative-
stranded RNA viruses. The virion comprises a core ribonu-
cleocapsid complex surrounded by a lipid envelope which is
derived from the host cell plasma membrane. The ∼19kb
noninfectious genome encodes seven structural proteins
with the following gene order: 3  leader, a nucleocapsid
protein (NP), structural virion protein (VP) 35 (VP35),
a matrix protein VP40, glycoprotein (GP), two additional
structural proteins VP30, VP24, and the RNA-dependent
RNA polymerase L protein, and 5  trailer [2]. VP24 and
VP35 have been shown to act as interferon antagonists [3].
Studies employing reconstituted replication systems showed
that transcription/replication of MARV requires three of the
four proteins (NP, VP35, L), while transcription/replication
ofEBOVrequiresallfourproteins[4].ForEBOVandMARV,
the virus encodes a type I transmembrane glycoprotein (GP)
that is responsible for virus binding and entry into host cells,
is the only protein known to be located on the surface of the
virions and infected cells, and is the likely target of protective
antibodies.
The ﬁloviruses cause severe acute hemorrhagic fever in
humans, with a high mortality rates. Disease onset is sudden,
beginning with fever, malaise, chills, loss of appetite, muscle
aches, and headache. These may be followed by abdominal
pain, nausea, vomiting, cough, sore throat, arthralgia, diar-
rhea, and hemorrhage, with death occurring from shock.
A maculopapular rash often develops 5 to 7 days into the
illness. The mortality observed in outbreaks has ranged from2 Journal of Biomedicine and Biotechnology
25% to 90% [5, 6] with ZEBOV causing extensive pathology
and having the highest mortality rates. The virus is found
throughout the body, but the highest concentrations are in
the liver, kidney, spleen, and lungs. Filoviruses primarily
replicate in mononuclear phagocytes [7, 8] and induce
production of proinﬂammatory cytokines by infected cells
[9], which may explain the damage to the lymphatic organs.
Outbreaks of ﬁlovirus infection cannot be predicted
despite growing evidence that bats are among, and perhaps
principle among, the natural reservoirs and/or vector(s)
[10, 11]. Including the human suﬀering these disease inﬂict
where the diseases are endemic, the viruses also have the
potential for accidental importation from epidemic regions.
Additionally, ﬁloviruses are stable and can be infectious as
aerosols, by the oral and conjunctival routes [8, 12–16]
making them a bioweapon concern. Supportive care remains
the only option for treating patients infected during natural
orintentional diseaseoutbreaks.Therefore,itis important to
developvaccinesandtherapeuticsthatcanbeinpreventative,
postexposure, or therapeutic settings.
2. FilovirusVaccines andTherapies
There are several promising vaccine candidates that have
demonstrated immunogenicity and eﬃcacy in animal mod-
elsofdisease.TheseplatformsincludetheVenezuelanequine
encephalitis (VEE) virus-like replicon (VRP), adenovirus
5 (Ad5), vesicular stomatitis virus-(VSV-) based vaccines,
and virus-like particles (VLPs) [17, 18]. In early studies,
classical approaches were attempted for ﬁlovirus vaccines
attenuated or inactivated viral preparations; however, pro-
tection in primate animal models showed variable and
moderate success coupled with the risk of revertants or
incomplete inactivation result in these approaches being
unacceptable for future use in humans [19–27]. Genetic,
virus-vectored, and subunit vaccines have been evaluated in
recent years. Early publications reported partial to complete
protection against virus challenge in rodents after gene-
gun administration of DNA plasmids containing GP genes,
but provided incomplete protection to NHP [19, 28, 29],
but more recently, Geisbert et al. demonstrated complete
protection against MARV using a DNA vaccine approach
[30]. Puriﬁed glycoprotein-based vaccine candidates showed
moderate success to date in guinea pigs although the quality,
potency, and purity of these protein preparations are unclear
[28, 31, 32]. Vector-based approaches including replication-
incompetent VEE virus replicons, replication-incompetent
adenoviral (Ad5) vectored vaccines, as well as live recombi-
nant virus-based approaches using vesicular stomatitis virus
(VSV) or parainﬂuenza have shown signiﬁcant promise in
both rodents and NHP models [23, 26, 33–43]. The vaccine
candidates, to date, have identiﬁed immunogens, usually the
glycoprotein, established minimal eﬀective doses, and most
importantly demonstrated eﬃcacy in the highly sensitive
macaque models of ﬁlovirus disease. In almost all cases of
successful vaccination, an association with ﬁlovirus-speciﬁc
IgG with protection has been identiﬁed [44].
Currently, there are no medical interventions approved
for the treatment of ﬁlovirus infections in humans and
current standard of care is supportive medical treatment
(e.g., ﬂuid replacement, transfusions, antibiotics for pre-
vention of secondary infections) [45]. Multiple approaches
have been tested and demonstrated partial to complete
protection against lethality in nonhuman primate models
including treatment of the coagulopathic diathesis by use of
nematode anticoagulant protein c2 (a potent inhibitor of tis-
sue factor-initiated blood coagulation) [46] or recombinant
human-activated protein C (which has a broad spectrum of
coagulation-modulating activity) [47], immune modulators
such as human-activated protein C [47] therapeutic vaccines
[48–50], and gene-speciﬁc antivirals [51–54]. The VSV
system has been shown to provide highly robust protection
when administered to nonhuman primates in a postex-
posure setting and likely induces both nonspeciﬁc innate
stimulation as well as virus-speciﬁc immunity [48–50].
AntiviralssuchassiRNAandphosphodiamidatemorpholino
oligomers that directly inhibit EBOV or MARV replication
also appear to be lead candidates for treatment of highly
lethal ﬁlovirus infections based on highly successful eﬃcacy
studies in NHP [51–54]. In all cases, lower peak viral loads
areassociatedwithmorepromisingoutcomesinhumansand
NHP [51, 55].
In this review, we have summarized the ﬁndings of
recent investigations on cellular responses against EBOV
and their importance in survival from lethal ﬁlovirus chal-
lenge. Understanding the protective immune responses and
immunopathology induced by these viruses may be critical
to the advancement of the ﬁlovirus vaccine platforms and
potentially to postexposure treatment strategies for ﬁlovirus-
infected individuals.
3. Global ImmuneResponses andImmune
Interactionsafter FilovirusInfection
3.1. Impaired Innate Immune Responses during Filovirus
Infection. The innate immune system is the cornerstone
for recognizing and eﬀectively eliminating viral infections;
rapid detection of the microbe and subsequent activation
of the host innate immune response is key for devel-
oping eﬀective adaptive immunity to invading pathogens.
Antigen-presentingcellsincludingmonocytes,macrophages,
and dendritic cells (DCs) are central in both activation
of innate immunity and initiation of adaptive immunity.
Antigen-presenting cells drive immune responses by induc-
ing cytokines and chemokines; antigen presentation; inter-
actions with B, T, and NK cells; and direct cytotoxic activity
against target cells [56, 57]. Several key observations support
a critical role for innate immunity in ﬁlovirus infections.
First, survivors of ﬁlovirus infection have an early and
short-lived rise in serum chemokines, indicative of innate
immune system induction [58–63]. In a recent and relatively
large study of EBOV-infected individuals, nonsurvivors
developextremelyhighlevels(5–1000X)ofproinﬂammatory
cytokines (IL-1β, IL-1RA, IL-6, IL-8, IL-15, and IL-16) and
chemokines (MIP-1α,M I P - 1 β,M C P - 1 ,M I F ,I P - 1 0G R O - α,
and eotaxin) that began rising shortly after disease onset and
continuing until the last sampling within 2-3 days before
death [63]. Infected monocytes and macrophages may beJournal of Biomedicine and Biotechnology 3
the primary mediators of this inﬂammatory response and
the resulting cytokine and chemokine secretion increases the
permeability of endothelial layer and causes induction of
shock[9,64].Interestingly,bothsurvivorsandnon-survivors
do not diﬀer in their serum levels of important regulators
of adaptive immunity such as IFN-α,I F N - γ, IL-12, IL-17,
or TNF [63]. Consistently with these ﬁndings, the ﬁloviruses
encode interferon antagonists VP24 and VP35, which block
interferon production and inhibit downstream interferon
signaling [65].
Second, ﬁloviruses evade the immune system by prevent-
ing the maturation of DC, the cornerstone of innate and
adaptive immunity [66, 67], as well as encoding for multiple
viral proteins that add in evasion of interferon responses
(reviewed in [65]). These data suggest that EBOV may block
DC maturation after infection, thereby inhibiting activation
of lymphocytes and eliminating those subsets that are most
likely to be capable of mounting an eﬀective response to
the virus. Both EBOV and MARV readily infect and rapidly
replicate in antigen-presenting cells such as monocytes,
macrophages, and DCs resulting in the production of
large amounts of progeny virus [9, 64, 66–70]. In EBOV-
infected macaques, the number of circulating HLA-DR+
cells increases 10X in the blood after infection suggesting
that infected DCs may disseminate virus throughout the
body after traﬃcking from the infection site [71]. Despite
increased numbers in the circulation, DCs infected by
ﬁloviruses fail to mature or become activated and, therefore,
fail to induce appropriate NK-, B-, and T cell responses after
infection [66, 67]. Activity of monocytes and macrophages
may also be dysregulated, although responses of monocytes
and macrophages to ﬁlovirus infection are a divisive issue in
ﬁlovirology [9, 64, 66, 70]. Certainly, the downstream eﬀects
of antigen-presenting cell dysfunction are profound with a
marked lack of adaptive immunity noted in fatal cases of
ﬁlovirus infection.
Third, activation and maintenance of natural killer
(NK) cells appears to be vital to protection against lethal
ﬁlovirus infection [50, 72, 73]; however, NK cells and
other lymphocytes are depleted during ﬁlovirus infection
of human and NHPs [55, 59, 60, 71]. The disappearance
of NK and T cells in the periphery is presumptively due
to apoptosis by a yet unidentiﬁed mechanism, although
a Fas/FasL interaction is likely involved [14, 55, 63, 74].
A potential correlation of NK cells with rapid protection
againstﬁlovirushemorrhagic fever,induced by rVSV vaccine
in a postexposure treatment study in nonhuman primates,
was observed [73]. VLPs can also induce rapid and potent
innate immune responses in rodents injected with VLPs 1–3
days before challenge with EBOV [72]. Injection with VLPs
recruited almost twice the number of NK cells in both the
mediastinal lymph node and spleen compared to animals
receivingPBSalone[72],suggestingthatVLPadministration
induces NK cell proliferation and/or traﬃcking in lymphoid
tissues VLP-pretreatment of mice lacking functional NK
cells [75] or mice depleted of NK cells using antiasialoGM1
antibodiesdidnotprotectfromEBOVinfection,unlikeVLP-
injectedwild-typeC57Bl/6mice[72].Furthermore,adoptive
transfer of NK cells stimulated with VLPs protected na¨ ıve
mice against EBOV infection and the mechanism of this
protective innate immunity requires perforin, but not IFN-
γ,[ 72]. Recently, Wauquier et al. suggested a role of the killer
immunoglobulin receptor (KIR) repertoire in fatal outcomes
of patients infected with EBOV. KIRs are expressed on the
s u r f a c eo fN Ka n dTc e l l sa n di n v o l v e di na c t i v a t i o no fN K
cells [63, 76]. Together, these data point to a critical role
for NK cells in survival from ﬁlovirus infection and suggest
the cytolytic “killer” functions of NK cells are an important
mechanism in promoting survival from EBOV infection.
Subversion of innate immunity combined with a lag in
activation of adaptive immune responses likely results in
uncontrolled, disseminated, ﬁlovirus infection [66–68].
3.2. Role of B and T Cells in Filovirus Infection. Infected
individuals who succumb to ﬁlovirus infection fail to mount
a substantial cellular or humoral immune response. In non-
survivors,activationofimmunecellsandsecretionofcytoki-
nes and chemokines are detected early in infection; however,
these early cellular responses appear to be attenuated and are
not detectable at the time of death while the levels of proin-
ﬂammatory cytokines and chemokines reach enormous
levels before a fatal outcome. Fatal cases of ﬁlovirus hem-
orrhagic fever are associated by a marked lack of detectable
adaptive immunity. After onset of symptoms, a massive loss
of CD4+ and CD8+ T cells occurs. In fatal cases of disease,
gross numbers of CD4+ and CD8+ T cells are greatly
reduced in non-survivors as compared to survivor (6–10%
versus 20–40%, resp. [63]). Similarly, in a cynomolgus
macaque model of EBOV hemorrhagic fever, CD4+ and
CD8+ lymphocyte counts rapidly declined 60–70% within
the ﬁrst 4 days afterinfection [71] and phenotypic analysisof
the T lymphocyte subsets demonstrated the lack of a robust
immuneresponsetotheinfection.Inthenonhumanprimate
model, apoptosis of CD8+ T cells was observed within 2 days
of infection. Similar ﬁndings in nonsurvivor human cases
and nonhuman primates that succumb to ﬁlovirus infection
show an increase in the expression of CD95 (Fas) suggests
a mechanism for apoptosis involving the Fas/Fas-L cascade
[63, 71, 77] and both upregulation of Fas/FasL and TRAIL
are observed in ﬁlovirus-infected PBMS or monocytic cells
[78]. Interestingly, the number of CD20+ Bl y m p h o c y t e si n
the blood does not appear to be signiﬁcantly altered after
ﬁlovirus infection using the nonhuman primate infection
model despite the apparent lack of virus-speciﬁc IgG in
nonhuman primates and nonsurviving human patients [55,
71].
In EBOV survivors, the early and apparently regulated
inﬂammatory response is quickly followed by a detectable
T cell response with an increase in markers suggesting the
activation of cytotoxic T cells (CTL) [55, 58, 63]. Concomi-
tant with detectable T cell responses, an early and transient
IgM is followed quickly by increasing levels of EBOV-speciﬁc
IgG in EBOV survivors [55, 58, 79]. Survivors develop rapid
immune responses that likely clear circulating EBOV early,
indicating that a swift induction of the appropriate immune
responses in humans can result in survival from ﬁlovirus
infection [55].4 Journal of Biomedicine and Biotechnology
MechanisticstudiesregardingtheroleofBandTcellsare
diﬃcult in nonhuman primate models; therefore, a number
of studies examining the role of B and T cells in protection
from lethal ﬁlovirus disease have been conducted using a
mouse model of EBOV (requiring a mouse-adapted strain
for lethal disease [80]). Both CD4+ and CD8+ T cells are
depleted in the blood and spleens after EBOV infection
of mice, apparently due to apoptosis, similarly to humans
and nonhuman primates; however, subsequent studies have
shown that T cell function is maintained in the remaining
cells despite their massive loss in numbers [81, 82]. The
number of functional CD8+ T cells that are generated at
the late phase of infection is likely too low to control high
viraltitersalthoughtheyaresuﬃcientupontransfert onewly
infected animals to control the disease and the damage done
by the infection could be too severe to overcome at the time
the adaptive immune system can mount a response [82].
The mechanisms of lymphocyte apoptosis have been studied
using the mouse model of EBOV and it appears that both
the intrinsic and extrinsic apoptotic pathways play a role, as
evidenced by infection of various knockout mouse models
[83]. Unlike the NHP model of EBOV, mice infected with
mouse-adapted EBOV have steep declines in circulating B
cells although the number of splenic B cells remains constant
after infection [81] .G u p t ae ta l .d e m o n s t r a t e dac r u c i a lr o l e
for CD8+ T cells in the initial clearance of the virus after
primary and secondary infections [84]. In this study, they
also showed that neither CD4+ T cells nor antibodies were
required for immediate protection but in the absence of both
B cells and CD4+ T cells, virus antigen was detected late
after infection and morbidity was also observed long after
the normal time to death [84]. These mouse data indicate
that while immediate control of ﬁlovirus infection may be
achieved by CD8+ T cells alone, B and CD4+ T cells are
important for long-term control (and possibly clearance) of
virus replication.
4. Immune Mechanisms of Protection from
FilovirusInfection
4.1. Humoral Responses and Role of Antibodies in Pro-
tection Filovirus Infection. Humoral responses have long
been deemed important for protective immunity against
viral infections and, indeed, all those vaccines shown to
provide 100% protection from lethal challenge in NHP
have demonstrated the ability to drive ﬁlovirus-speciﬁc
IgG [44]. In the case of the recombinant Ad5 vaccines,
survival can be reliably predicted when a vaccinated NHP
achieves a certain IgG titer, suggesting that this may be a
potential marker for prediction of protection [85]. In the
case of VLP vaccines, vaccinated B cell-deﬁcient mice do not
mount antibody responses and are not protected from lethal
ﬁlovirus challenge [86] and a similar relationship between
IgG titers against GP and protection from challenge in VLP-
vaccinated NHPs is observed for both ZEBOV and MARV
(unpublished observation).
A great deal of eﬀort has focused on the passive transfer
ofantibodiestoachieveprotectionanddemonstrateadeﬁni-
tive requirement for antibodies in mediating protection
from ﬁlovirus infection. Passive transfer of serum containing
antibodies or puriﬁed IgG speciﬁc to EBOV or MARV can
provide protection in rodent models of disease [87–90];
it is reported sporadically in NHP models [27, 85, 91–
93]. It may be hypothesized that the inability to date to
repeatedly demonstrate protection in NHP using antibody-
based therapeutics is due to limitations on dosages and
frequency of treatment, although a cellular component may
be critical for protection whether it is part of the antibody
therapy or induced naturally after infection. The serum and
antibodystudieshavefocusedonvaccine-inducedpolyclonal
antibodies or monoclonal antibodies to EBOV or MARV
GP [87–90]. Antibodies speciﬁc for other viral proteins have
been unsuccessful in challenge studies in rodents [94, 95].
After successful protection after immunotherapy, de novo
immune responses were observed in passively transferred
animals. Most notably the induction of virus-speciﬁc func-
tional T cell responses to other viral proteins not present
in the original passive transfer inoculum has been reported
emphasizing the role of T cell responses to protection even
during passive transfer [96]. In these models, the antibody
likely provides control of viral replication while de novo
functional and speciﬁc T cell responses are generated to
limit and clear virus infection. Studies are underway to
more speciﬁcally and thoroughly assess antibody treatment
regimens in NHP models and the evaluation of subsequent
immune responses by the treated host.
4.2.RoleofTCellsinProtectiveEﬃcacyagainstFilovirusHem-
orrhagic Fever. A critical role in vaccine-induced protection
was identiﬁed for T cells by VLP vaccination of α/β-T cell
deﬁcientmiceandfurtherreﬁnedtoanabsoluterequirement
forCD8+ Tcellsusingβ2m-deﬁcientmice[86].Additionally,
multiple CD8+ CTL epitope-speciﬁc responses for EBOV
and MARV have been identiﬁed in mice [86, 96, 102], which
are summarized in Tables 1 and 2. In a thorough study of
murineCD8Tcellresponses,micewerevaccinatedwithVRP
containing each of the EBOV antigens (GP, NP, VP24, VP30,
VP35, and VP40; all viral proteins except the polymerase
[96]) and CD8+ T cells speciﬁc for the viral proteins
were identiﬁed using splenocytes from vaccinated mice
by ﬂow cytometry intracellular cytokine assays. Adoptive
transfer of the CD8+ cytotoxic T cells was performed using
cells expanded by peptide restimulation and these studies
demonstrated the ability to protect naive mice from EBOV
challenge. Transfer of MARV GP- and NP-speciﬁc CD8+
T cells can also provide protection against lethal infection
in na¨ ıve mice [102]. It is important to note that in these
studies other CD8+ T cell epitope virus-speciﬁc responses
were detected but were not demonstrated to be protective;
however,thesenonfunctionalCD8+ responseswerelesslikely
to demonstrate ex vivo lytic activity [96]. Together these
studies demonstrate that adoptive transfer of functional
virus-speciﬁc CD8+ T cell responses can provide protection
in rodent models of disease. Importantly, preliminary data
have also suggested a role for T cells in viral clearance in
NHP by immunodepletion of vaccinated animals [91]. By
targeting the T cell surface antigen CD3 with a mAb toxin
conjugate, FN18-CRM9, that depleted circulating CD3+ TJournal of Biomedicine and Biotechnology 5
Table 1: ZEBOV protein sequences recognized by murine CD8+ T cells. The table is adapted and expanded from [97].
ZEBOV protein Epitope sequence Amino acid position Restriction Protectivea Reference
Glycoprotein
VSTGTGPGAGDFAFHK 141–155 H-2d Yes [96, 98]
LYDRLASTVI 161–169 H-2d NT [25, 86, 98]
EYLFEVDNL 231–239 H-2d NT [25, 98]
WIPYFGPAAEGIYTE 531–545 H-2b No [86, 96]
TELRTFSI 577–584 H-2k NT [99]
Nucleoprotein
VYQVNNLEEIC 44–52 H-2b Yes [37, 96, 100]
GQFLFASL 148–156 H-2b Yes [96]
FLSFASLFL 150–159 HLA-A2.1 NT [101]
RLMRTNFLI 202–210 HLA-A2.1 NT [101]
SFKAALSSLA 279–287 H-2d Yes [96, 100]
FQQTNAMVT 388–396 H-2b NT [100]
KLTEAITAA 404–412 HLA-A2.1 NT [101]
DAVLYYHMM 663–671 H-2b Yes [96]
VP24
KFINKLDALH 159–168 H-2d Yes
NYNGLLSSI 171–179 H-2d Yes [96]
PGPAKFSLL 214–222 H-2d Yes
VP30
KFSKSQLSLLCETHLR 181–196 H-2d Yes
H-2b Yes
DLQSLIMFITAFLNI 231–245 H-2d Yes [96]
H-2b Yes
VP35
CDIENNPGL 45–53 H-2b Yes
MVAKYDHL 138–145 H-2b Yes
TVPQSVREAFNNL 190–202 H-2d Yes [96]
RNIMYDHL 225–323 H-2b Yes
PGFGTAFHQLVQVICK 233–248 H-2d Yes
VP40
LRIGNQAFLQEFVLPP 150–165 H-2b Yes [86, 96]
AFLQEFVLPPVQLPQ 160–175 H-2d Yes [96]
YFTFDLTALK 171–180 H-2d Yes [86, 96]
TESPEKIQAI 232–241 H-2d Yes [86, 96]
aProtection from lethal challenge demonstrated by either peptide vaccination or by adoptive transfer experiments (Yes, >50% protection observed).
NT: Not tested.
lymphocytes by >85% relative to starting levels, macaques
vaccinated and treated with irrelevant IgG but not those
animals vaccinated with ZEBOV GP-expressing adenovirus
a n dd e p l e t e do fC D 3 + T cells using FN18-CRM9 survived,
suggesting a key role for T cells in protection using the
adenovirus-based vaccine [91]. Since CD8+ T cell responses
against ZEBOV are observed in macaques vaccinated with
the adenovirus-based vaccine, the authors then used a CD8
α chain-speciﬁc antibody, cM-T807, which eﬃciently clears
CD8+ cells from blood, spleen, lymph nodes, and liver.
In this study, four of ﬁve cM-T807 treated and previously
vaccinated macaques succumbed to ZEBOV while all na¨ ıve
controls animals died and those vaccinated and not immun-
odepleted all survived. A statistically signiﬁcant decrease in
protection was observed in the cM-T807 immuno-depleted
vaccinated animals compared to the not immunodepleted
and vaccinated; however, an extension in the time to death
(TTD) was observed when comparing the immunodepleted,
vaccinated macaques (TTD days 10–14) as compared to
the two na¨ ıve animals (TTD day 8 for both). Together,
these data suggest that CD8+ Tc e l l sa r eak e yc o m p o n e n t
of protection mediated by the GP-expressing recombinant
adenovirus vaccine in the context of a ZEBOV challenge but
there may be other immune mechanisms involved [91].
Studies have also demonstrated a less important role for
CD4+ T cells in protection by ﬁlovirus vaccines [86] and,
unfortunately, the role of CD4+ T cells was not assessed
in the aforementioned mechanistic studies in nonhuman
primates by Sullivan et al. [91] Existing eﬀorts are focused
on the identiﬁcation of CD4+ T cell responses and their
role in EBOV and MARV infection, especially given their
dominance in responses in vaccinated humans [103, 104].
5. CriticalRole for CTL Responses inProtective
Efﬁcacy againstLethalFilovirusDisease
5.1. Identiﬁcation of Novel CD8 CTL Epitopes Recognized
by EBOV- and MARV-Speciﬁc CTLs. The discovery and6 Journal of Biomedicine and Biotechnology
Table 2: MARV protein sequences recognized by murine H-2d CD8+ T cells. Summary of data is from [102].
MARV protein 15-mer peptide sequence Minimal peptidea Amino acid position Adoptive transfer
protectionb
Glycoprotein
FLISLILIQGTKNLP ILIQGTKNL 11–19 50
ILIQGTKNLPILEIA QGTKNLPIL 14–22 20
TCYNISVTDPSGKSL VTDPSGKSL 97–105 NT
SGKSLLLDPPTNIRD LLLDPPTNI 105–113 0
SPPPTPSSTAQHLVY TPSSTAQHL 420–428 0
GILLLLSIAVLIALS LLLSIAVLI 659–667 100
LSIAVLIALSCICRI LSIAVLIAL 661–669 20
LIALSCICRIFTKYI IALSCICRI 667–675 40
Nucleoprotein
AINSGIDLGDLLEGG NSGIDLGDL 43–51 80
KFNTSPVAKYLRDAG NTSPVAKYL 73–81 20
EPHYSPLILALKTLE HYSPLILAL 108–116 10
VP40 QHKNPNNGPLLAISG KNPNNGPLL 218–226 40
a9 mer peptide sequence derived from HLA binding predictions.
bPercentage of animals protected from lethal challenge with mouse-adapted Marburg virus after adoptive transfer of CD8 lymphocytes speciﬁc for the 9-mer
peptide sequences.
NT: not tested.
identiﬁcation of virus-speciﬁc CTL epitopes have primar-
ily been based on computer algorithms or the use of
overlapping synthetic peptides of the viral proteins. The
protective capacity of the CTL virus-speciﬁc epitopes has
been demonstrated in passive transfer studies, vaccination,
and in the analysis of postchallenge immune responses in
mice [82, 86, 96, 102]. Interestingly, solid protective eﬃcacy
of adoptively transferred CD8+ epitopes has been strongly
associated with lytic function, primarily based on chromium
release assays. Improved algorithms, lower-cost overlapping
peptides, and the use of HLA binding tetramers and other
classImethodologieswillassisttheassessmentofhumanand
NHP responses. Future eﬀorts will be focused on the use of
these tools and emerging tools to identify CD8+ and CD4+
epitopes in mice and CD8+ and CD4+ T cell responses NHP
and humans.
To date, the use of tetramer and similar technologies
oﬀers the ability to analyze the CD8+ T cell virus epitope-
speciﬁc frequency, phenotypes, and functional abilities with-
out ex vivo expansion. However, with macaque models of
disease, this powerful approach is limited for a variety of rea-
sons. First, most vaccine work has focused on the use of the
cynomolgus macaque (Macaca fascicularis) animal model,
for which limited deﬁned Mamu major histocompatibility
complex class I molecules are available for use in cellular
assays. Second, the rhesus macaque model (Macaca mulatta)
has two subspecies, the Indian Rhesus and the Chinese
Rhesus, that have been shown to have diﬀerent genetic
backgrounds and have diﬀerent disease outcomes for some
v i r u si n f e c t i o n ss u c ha sH I V[ 105–108]. Most importantly,
the common reagents for Mamu class I haplotypes used in
otherdiseases(i.e.,HIV)arerarelyseenintheChineserhesus
subspecies used in ﬁlovirus research. Switching to Indian
rhesus macaques could possibly alter the disease course, as
is seen with cynomolgus versus rhesus macaques, and would
complicate future studies because the subspecies availability
is more limited than Chinese rhesus. Therefore, better
deﬁning the Mamu class I haplotypes and development of
common Mamu class I cellular assays will be critical for
future studies to identify important T cell responses in
protected macaques.
5.2. Potential for CTLs as a Cocorrelate of Protection in
NHP Studies. Nonlethal infection or vaccination generates
complex responses in the host, which include innate and
adaptive arms of the immune system. For ﬁlovirus vaccines,
successful vaccination has generated a protective immune
response protecting animals from lethal virus challenges.
While both antibody responses and cellular responses have
been monitored in past studies, the analysis of these
responses was secondary to the objective of assessing the
vaccine candidate’s eﬃcacy in the animal model. While we
are unsure of the contribution of B and T cell responses
during vaccination, the collective data suggest that both are
necessary for viral clearance [44, 85, 86]. Currently, the
focus has shifted to advancing the discovery of correlate(s)
and surrogate(s) assays of immunity after vaccination. These
steps are critical to advance the vaccines through the FDA
“animal rule” licensure and eventual human-use of the
vaccine(s) [109].
After successful vaccination, adaptive responses to the
glycoprotein encompass both humoral and cellular immune
responses [44]. Existing assays in the laboratory have relied
on assessing the antibody titers and cellular responses
(CD4+ and CD8+ T cell responses) after vaccination or
virus exposure. For assessing antibody responses, virus GP-
speciﬁc IgG antibody titers have been assessed by quanti-
tative antigen ELISA and by assessing the functionality of
these responses in virus-neutralizing assays [85]. In mice
and, retrospectively, in most NHP studies, antibody titers
against EBOV GP and T cell responses correlated well
with successful vaccination [96]. However, these assays areJournal of Biomedicine and Biotechnology 7
not always predictive as high titer nonprotective antibody
responses have been observed (unpublished observations)
and nonneutralizing but protective antibody responses have
been described [87]. Therefore, as described by Sullivan et
al., T cell responses are proposed as a cocorrelate with the
antibody data from vaccinated animals [85].
5.3. Current Status of CTL Assays for Filovirus Vaccine Stud-
ies: Measuring “Good” Cellular Immune Responses. Without
assessing ELISA antibody titers, examining T cell responses
after vaccination has been less predictive when used in out-
bred populations, speciﬁcally macaques. This is likely due
to the complexity of measuring cellular immunity following
vaccination.Measuringcellularimmuneresponsesisdiﬃcult
since the assays are laborious, tedious, diﬃcult to replicate,
and expensive. Likewise, immunogen quality (peptides or
protein) used in the assays is paramount and currently
poorly understood for ﬁloviruses. Unlike most humoral
assays, cellular assays are typically performed ex vivo,m a y
require in vitro stimulation, preparation of autologous
target cells and require diﬃcult-to-obtain reagents and
equipment. In addition, the performance criteria for these
assays are optimal with freshly isolated, not cryopreserved,
peripheral blood mononuclear cells (PBMCs). To maximize
the ability to measure cellular responses, a number of
assays have been utilized to assess eﬀector functions of
CD8+ and CD4+ T cells. The analysis of cellular responses
has been determined by various methods including T cell
proliferation (lymphoproliferative assays (LPA)), chromium
release assays, Enzyme-linked immunosorbent spot assays
(ELISpot), interferon gamma release assays, and intracellular
cytokine staining (ICC) assays.
To date, LFA and chromium release assays have been
limited to evaluating immune response in rodents and
primarily in mice. LFAs are unique in that they allow the
assessment of both CD4+ and CD8+ or when fractionated
CD4+ or CD8+ T cell proliferation. In the presence of
radioactive (i.e., thymidine) or nonradioactive molecules,
which are incorporated into DNA during proliferation, a
stimulation index can be determined for a protein or peptide
antigen. Similarly, the chromium release assay is a means to
measure speciﬁc lysis of target cells expressing antigen by
CD8+ T cells; however the assay has been primarily limited
to studies with clearly deﬁned MHC systems and primarily
for analyzing T cell responses of vaccinated in-bred mice.
Thetwoprimaryassaysutilizedwithmacaqueshavebeen
ELISpot- and ICC-based assays. Both assays provide semi-
quantitative analysis of the total T lymphocyte responses or
analysis of indicators of T cell activation such as cytokine
production in ex vivo from vaccine-induced T cells or virus
speciﬁc responses following infection. In EliSPOT or ICS,
the percentage of cytokine producing (IFNγ,I L - 2 ,o rT N F -
α)C D 8 + or CD4+ T cells is measured [41, 48, 110–112].
The ELISPOT assay is considered by many to be a gold
standard for monitoring speciﬁc cellular immune responses,
especially in humans. The assay can detect single cells
secreting molecules primarily cytokines following exposure
to a speciﬁc antigen [112–114]. Overall the assay is highly
sensitive, quantitative, easy to use, and amenable to high
throughput [115]. The IFNγ ELISPOT has been widely
used in other vaccine eﬀorts (i.e., HIV, Tuberculosis) to
assess the quantiﬁcation and characterization of the CD8+
T cell responses [113]. Thus it has several unique advantages
including the following (1) it provides a reliable and suitable
method to directly measure antigen-speciﬁc T cells with
limited ex vivo expansion of cells during the assay, (2) it
typically requires fewer cells and can utilize cryopreserved
cells, (3) it has been correlated to provide similar immune
responses assessments in both macaques and humans [116],
and (4) equipment requirements are lower and overall less
technically diﬃcult to perform than ICC assays. Despite the
many positive attributes of the assay, the assay was used in
rodent studies but was less predictive than other cellular
assays. [96]. Furthermore, the predictive power of this assay
in humans has become questionable since the approach did
not accurately predict vaccine protection in a recent HIV
vaccine trail [117]. Improvements in ELISpot assays and
reagents and the potential of multidimensional, dual color
cytokine ELISpot assays [118] may increase the value of this
approach in the future.
ICC methods have been the primary method to assess
cellular responses in macaques. To date, these assays have
relied on three- to four-color ﬂow cytometry. In these assays,
irradiated virus, recombinant proteins, or overlapping pep-
tides have been used to stimulate rodent or macaque PBMCs
ex vivo [41, 86, 96, 102, 119, 120]. As expected, there are
numerous “positive” responses after vaccination, likely due
tothevastactivationofspeciﬁcandnonantigen-speciﬁc(i.e.,
vector directed responses) lymphocyte responses generated
after antigen exposure by the various vaccine platforms
which often involve a viral vector or adjuvant. As described
by Sullivan et al., we have also observed low CD4+ and
CD8+ T cell responses (near the assay limits of detection)
or inconsistently observed responses in the same macaque
after vaccination ([120] and unpublished data) and, thus,
the reliability of these responses has been questioned as
the responses are rarely consistently observed after booster
vaccinations, challenge, or in convalescent animals. The
traditional ex vivo assessment of cellular immunity after
vaccination likely lacks the sensitivity needed to detect the
relevant determinants of cell-mediated immunity and are
unable to diﬀerentiate the functional attributes (memory
or eﬀector phenotypes) of the responses observed. Further-
more,samplingbloodvolumelimitsseverelyimpairtheanal-
ysis that can be achieved after vaccination in experimental
animal models. The use of out-bred models is more diﬃcult
than the described inbred mouse studies due to the various
MHCs within the models and further complicated by the
lack of reagents to monitor cellular responses. For example,
while there are easily obtainable methods to analyze CD8+
T cell responses in in-bred mice with MHC class I tetramer
molecule technologies, there are limited reagents available
for macaques to monitor virus-speciﬁc cellular immunity.
Newer, more-sensitive methods for analysis of cellular
immunity oﬀer promise for more-detailed assessment of T
cell phenotype and function. Another emerging approach
to measure cellular responses is the use of multiparameter
ﬂow cytometry. The aforementioned techniques used for8 Journal of Biomedicine and Biotechnology
ﬁlovirusesrevealacellularreactivitytovirusprotein(s);how-
ever the data lack critical information that can discriminate
between “good” or nonprotective immunity. Thus, the issue
istherelativevaluesoftheeasilyobtaineddata(magnitudeof
the response to antigen) and the more diﬃcult assays which
ascertain the sensitivity/speciﬁcity of the immune response.
Thelateraspecthasbeendiﬃculttoassessinthepastandcan
be costly to obtain. Assays for both magnitude and quality of
the response have been best described by Roederer et al. for
the development of multicolor ﬂow cytometry methods to
assess T cell frequency and, more importantly, T cell quality
in memory and eﬀector cells [121, 122]. The key aspect is
that the clonal expansion of antigen-speciﬁc T cells results
in a heterogeneous population of epitope/antigen-speciﬁc
responses. These cells vary considerabl in functional capacity
and some may even lack function as determined by lytic
activity. Thus, an analysis of “magnitude” by ELISpot or
limited ICS, while being informative, lacks critical functional
information. Even within the functional subset of cells, there
are a variety of cells with varying functional potential with
some working as lytic eﬀector cells and others responsible
for organizing immune responses (speciﬁc cytokine and
chemo-attractant producers), to other clones that facilitate
proliferation of the clones and other immune cells needed
for the response.
Unfortunately, our understanding of these various func-
tional cell subsets is not clear. Therefore, a “good” vac-
cine cellular response can only be determined empirically
using animal model(s) and then translated to human-use.
The assays developed by Roederer et al. have deﬁned a
method that allows sampling of heterogeneous populations
of antigen-speciﬁc cells and their relative functional capac-
ities. Multiparametric ﬂow cytometry methods allow for
simultaneous T analysis of several parameters (∼four to ﬁve
parameters and growing [122]). These parameters are often
associated with speciﬁc functional capacities. Given proﬁles
can be associated with protective T cell responses when
compared to unprotected individuals or animals. The use
of this technology has enabled the assessment of the het-
erogeneous population of cells and correlates them to viral
loadsinHIV.Forexample,inHIVagivenlymphocyteproﬁle
was established for viral load in long-term non-progressors
(LTNP) versus progressors [121]. In those studies, a subset
of T cells with the greatest multicytokine producing capacity
is associated with virus suppression. In the assay, B and T
cell phenotypes can be assessed with precision on a single-
cell level by exploiting markers of lineage, homing proﬁle
and memory phenotypes. Such phenotypes can be deﬁned
further by their functional proﬁles such as eﬀectors, memory
or having the ability to express multiple cytokines (i.e., TNF-
α,I L - 2 ,a n dI N F - γ).
In initial work by Sullivan et al., they suggest that similar
proﬁles exist for protective responses to ﬁloviruses [85]a n d
the approach may be useful in bridging preclinical macaque
studies to human clinical studies. While prechallenge serum
antibody titers (IgG against GP by ELISA) have been fairly
goodatpredictingsurvivalinvaccinatedmacaquesfornearly
all of the vaccine platforms tested, the use of multiparameter
ﬂowcytometrytoanalyzespeciﬁcphenotypic andfunctional
markers of cellular immunity appears to enhance the ability
to predict protection after vaccination [85]. Therefore, the
useofadditionalimmunecorrelates,suchascellularimmune
assaysmaybeusefulinvaccinelicensureespeciallyasthevac-
cinesareassessedinclinicalstudieswithanimalsandhumans
as the translation of protection may vary between species.
Similar to studies described with rAd5-based vaccines, our
own studies with VLP- and VEE replicon-based vaccines
suggest that the ability of virus-speciﬁc T cells (CD4+ and
CD8+) to produce two or more cytokines and IgG titers to
the viral GP has been associated with a protective immunity
(unpublished observation). The use of this type of assay in
examininghumanresponsestoﬁlovirusvaccinesisdiscussed
hereinafter. While the ability to utilize novel methods to
assess cellular assays such as multiparameter (>10 colors)
ﬂow cytometry and mass spectrometry methods to assess
cellular response appears to be important for monitoring
prechallengeresponsesinvaccinatedanimals,theuseofthese
types of assays in ﬁlovirus-challenged animals is technically
constrained in many high-containment laboratories. New
biosafety level- (BSL-) 4 facility designs, optimization of
assays, and miniaturization of equipment should allow
the measurement of cellular responses which are currently
impractical.
5.4. Human Filovirus Vaccine Studies: An Opportunity to
Evaluate the Role of CTLs. Due to the nature of ﬁlovirus
hemorrhagic fever, eﬃcacy trials in humans are not ethical.
Primary objectives of clinical testing eﬀorts for ﬁlovirus
vaccines will be the safety and immunogenicity of diﬀerent
dosage levels of the candidate ﬁlovirus vaccine [85]. FDA
approval of a ﬁlovirus vaccine for broad (nonemergency)
use in humans will require licensure via the FDA “animal
rule” guidance having pivotal eﬃcacy studies in animals
(presumptivelyNHPmodelsthatmostcloselymimichuman
disease) being performed concurrently with clinical trials,
thus allowing correlates or surrogate markers of protection
identiﬁed in animals to be linked with the performance
of the vaccine candidates in humans [85, 109]. To date,
there have been two publications from the Vaccine Research
Center of NIAID, NIH regarding clinical trials testing safety
andimmunogenicityofDNAandadenovirus-basedﬁlovirus
vaccines [103, 104].
In the ﬁrst clinical trial of a ﬁlovirus vaccine, 27 subjects
were vaccinated in a dose-escalation study having four tiers
of 0, 2, 4, or 8mg of DNA given three times at >21 day
intervals [103]. The DNA vaccine consisted of three plasmid
components encoding the ZEBOV or SEBOV GP or the
ZEBOV NP. The vaccine was generally welltolerated with
only one subject in the 2mg dose group and two subjects
in the 8mg dose group not receiving all three injections. In
all vaccines receiving the Ebola DNA vaccine, virus-speciﬁc
antibody responses were observed; however, not all subjects
generated antibodies to all three components as measured by
western blotting and ELISA [103]. None of the subjects gen-
erated detectable virus-neutralizing antibodies [103]. T cell
responses were tested using intracellular cytokine staining
(ICS) and ELISPOT assays with stronger responses to
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immunogenic. CD4+ T cell responses were observed at some
point in the trial duration in all vaccinees; however, CD8+
T cell responses were observed less frequently (100% versus
30%) and to a lower extent [103]. While the results of
this trial were encouraging in demonstrating safety and
immunogenicity in humans, the DNA vaccine has not been
demonstrated to provide complete protection against EBOV
infection in NHP.
In the second clinical trial, a replication-defective aden-
ovirus serotype 5 (Ad5) vaccine expressing the ZEBOV and
SEBOV GPs was tested in 31 human volunteers with 23
receiving the Ad5 vaccine [104]. Three groups of patients
were administered one of two doses of vaccine (2 × 109
or 2 × 1010 VP, for example, “low” and “high” dose, resp.)
or placebo given once intramuscularly on day 0 and the
volunteers were followed for 48 weeks [104]. Mild local
site reactions were noted in a majority of patients receiving
v a c c i n e( 1 5o f2 3v e r s u s1o f8i nt h ep l a c e b og r o u p )
and mild-to-severe systemic symptoms were observed in
48% (11 of 23) of vaccinees versus 25% (two of eight
having mild systemic reactions) of those receiving a placebo
injection. Four weeks after the vaccination, 58% and 100%
of low- and high-dose vaccinees, respectively, were positive
for antibodies to SEBOV GP while 50% and 55% of low-
and high-dose vaccines were seropositive for ZEBOV GP by
ELISA.Overall,antibodyresponsesweremaintainedthrough
48 weeks in the low-dose group in 42% (SEBOV GP)
and 33% (ZEBOV GP) of vaccinees and in 60% (SEBOV
GP) and 40% (ZEBOV GP) of vaccinees in the high-dose
group. No positive antibody responses were observed in
placebo recipients. Preexisting immunity to Ad5 seemed
to aﬀect the outcome of vaccination, as Ad5-seronegative
subjects had a signiﬁcantly higher antibody titers, as well
as response rate, when compared to the Ad5-seropositive
subjects. Interestingly, using an ELISpot assay to assess bulk
T cell responses, slightly higher response rates were observed
inlow-dosevaccineeswhencomparedtohigh-dosevaccinees
(27% versus 25% for SEBOV GP and 45% versus 25% for
ZEBOV GP, resp.) at 4 weeks postvaccination. In contrast,
GP-speciﬁc CD4 responses were seen in 42% and 82% of
vaccinees in the low- and high-dose groups for SEBOV GP
and in 33% and 64% of vaccinees for ZEBOV GP. Overall,
CD8TcellresponsesweresigniﬁcantlylowerthantheCD4T
cellresponseswith8and9%oflow-andhigh-dosevaccinees
having detectable CD8 T cell responses to SEBOV GP and 0
and 27% of low- and high-dose vaccinees having CD8 T cell
responsestoZEBOVGPat4weekspostvaccination.Therate
of T cell responses in vaccinees did not seem to be aﬀected
by preexisting immunity to Ad5, although the number of
volunteers having T cell responses was low [104].
The reports for the ﬁrst two clinical trials of ﬁlovirus vac-
cines show the ability to successful induce ﬁlovirus-speciﬁc
humoralandcellularresponses[103,104].Theassaysusedto
detect T cellresponses in the ﬁrst two clinical trials for EBOV
vaccines were ICS (ﬂow cytometry-based) and ELISPOT
assay [103, 104]. In both assays, the most immunogenic
component wasthe SEBOV GP. The most prevalent response
discoveredwasthatofCD4+ Tcells,asdetectedusingtheICS
assay.TheICSassayappearedtobemuchmoresensitivethan
the ELISPOT assay, which detected T cell responses in far
fewer individuals [103, 104]. Given the apparent important
role of T cells in vaccine-mediated protection, the use of
a T cell assay in assessing immune responses to ﬁlovirus
vaccines will be important in human clinical trials and also
pivotal animal eﬃcacy trials. The challenge will be bridging
these highly technical and complicated assays into use for
large Phase 3 immunogenicity studies, where large numbers
of samples collected at multiple studies sites will likely be
required.
6. Conclusions andFutureDirections
Because of their lethality and other key properties that
characterize the ﬁloviruses as a bioweapon threat, a focused
eﬀort to develop medical countermeasures has been directed
against EBOV and MARV infections [123]. With the devel-
opment of mouse models of disease [80, 124], reagents for
examination and depletion of speciﬁc immune cell popu-
lations in nonhuman primates, and the success of vaccines
and therapeutics, the ability to tease the protective immune
response has been begun [85]. While humoral responses to
the virus are clearly important, there is mounting evidence
that ﬁlovirus-speciﬁc CD8+ CTLs are necessary for viral
control and clearance [86, 96]. The roles of T cells in
protection are being assessed as multiple vaccine candidates
a r et e s t e di nN H Pe ﬃcacy trials and, ultimately, in clinical
trial volunteers. Although we have learned a great deal about
the consequences of either an inadequate or robust CTL
response after vaccination or infection in various animal
models, few data are available from human survivors of
EBOV or MARV. T cell assays must be developed with
relevance to future human clinical studies in mind. Human
trials will require robust assays for monitoring immune
responses for eventual licensure of the human-use ﬁlovirus
vaccine(s).Forthispurpose,furtherinvestigationofimmune
responses in both natural ﬁlovirus infection and active
immunization in humans must be continued and expanded.
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